Targeting the YAP-BST2 Axis Overcomes Intrinsic Anti-PD-1 Resistance in Metastatic Gastric Cancer.

Authors

Weihong Zhang, Shilong Wang, Meng Wang, Ruixian Yu, Jingwu Yue, Lin Shao, Hui Zhang, Mengwen Zhu, Luyang Tian, Shuting Cheng, Weimin Qin, Yang Tang, Yi Han, Wenjia Wang, Liwei An, Yan Meng, Shi Jiao, Zhaocai Zhou

Published in

Advanced science (Weinheim, Baden-Wurttemberg, Germany). Pages e77708. Sep 21, 2026. Epub Sep 21, 2026.

Abstract

Intrinsic resistance to anti-PD-1 immunotherapy remains a major obstacle in treating metastatic gastric cancer (GC), particularly in tumors harboring concurrent YAP hyperactivation and TP53 loss. Here, using a genetically engineered mouse model with conditional YAP hyperactivation and Tp53 deletion in gastric Atp4b⁺ cells (AYP), we show this "double-hit" alone suffices to recapitulate human refractory GC, including histopathological heterogeneity, multi-organ metastasis, and intrinsic PD-1 resistance. We identified BST2 as a direct YAP-TEAD transcriptional target. In human GC, BST2-high tumor correlates with poor anti-PD-1 response. Mechanistically, tumor cell-derived BST2 engages the inhibitory receptor PIRA2 on neutrophils and liver Kupffer cells, instructing an immunosuppressive, pro-metastatic phenotype that inhibits T cells antitumor response and confers PD-1 resistance. Therapeutically, dual BST2/PD-1 blockade in the AYP model suppresses primary tumor growth and eradicates established liver metastases. Thus, YAP activation, cooperating with TP53 loss, fuels metastatic GC and immunotherapy resistance via BST2 induction.

PMID:
42765331
Bibliographic data and abstract were imported from PubMed on 21 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.